Analysis of incomplete data is a big challenge when integrating large-scale brain imaging datasets from different imaging modalities. 1 key finding →
Participants: 780 Evidence: low
Full summary, score breakdown and related studies → Original source
33,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Analysis of incomplete data is a big challenge when integrating large-scale brain imaging datasets from different imaging modalities. 1 key finding →
Participants: 780 Evidence: low
Full summary, score breakdown and related studies → Original source
Network characteristics in women may favor an accelerated brain-wide tau spread leading to a higher tau burden in women than men with MCI with implications for the greater female preponderance in Alzheimer's disease diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We compared accuracy of hippocampus and basal forebrain cholinergic system (BFCS) atrophy to predict cortical amyloid burden in 179 cognitively normal subjects (CN), 269 subjects with early stages of mild cognitive impairment (MCI), 136 subjects with late stages of MCI, and 86 subjects with Alzheimer's disease (AD) dementia retrieved from the Alzheimer's Disease Neuroimaging Initiative database. 4 key findings →
Participants: 269 Evidence: low
Full summary, score breakdown and related studies → Original source
Neurofilament light chain (NFL) has been recently introduced as a biomarker of early dementia. 18-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a proxy for regional hypometabolism in Alzheimer disease (AD). 1 key finding →
Participants: 149 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The epsilon4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for Alzheimer's disease (AD), but limited work has suggested that APOE genotype may modulate disease phenotype. 3 key findings →
Participants: 67 Evidence: low
Full summary, score breakdown and related studies → Original source
To acquire larger samples for answering complex questions in neuroscience, researchers have increasingly turned to multi-site neuroimaging studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia represents a growing public health burden with large social, racial, and ethnic disparities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Changes in several regions within the brain have been associated with progression from healthy aging to Alzheimer's disease (AD), including the hippocampus, entorhinal cortex, and the inferior parietal lobule (IPL). 2 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
Selecting a set of relevant markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has become a challenging task given the wealth of regional pathologic information that can be extracted from multimodal imaging data. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) is a prevalent and complex condition among older adults that often progresses into Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
However, most existing research focuses on only a single modality of biomarkers for diagnosis of AD and MCI, although recent studies have shown that different biomarkers may provide complementary information for the diagnosis of AD and MCI. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
For the last decade, it has been shown that neuroimaging can be a potential tool for the diagnosis of Alzheimer's Disease (AD) and its prodromal stage, Mild Cognitive Impairment (MCI), and also fusion of different modalities can further provide the complementary information to enhance diagnostic accuracy. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recently, many researchers have used graph theory to study the aberrant brain structures in Alzheimer's disease (AD) and have made great progress. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Accurately identifying the patients that have mild cognitive impairment (MCI) who will go on to develop Alzheimer's disease (AD) will become essential as new treatments will require identification of AD patients at earlier stages in the disease process. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In Alzheimer's disease patients, although amyloid deposition and CSF amyloid changes continued to "cascade", there was no evidence to suggest that amyloid and tau biomarkers predicted each other, although both amyloid deposition and CSF tau progression predicted cognitive decline independently. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain age prediction is a machine learning method that estimates an individual's chronological age from their neuroimaging scans. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The genetics dataset yielded two subtypes of AD characterized mainly by the presence/absence of the apolipoprotein E (APOE) ε4 genotype, but also involving differential presence of risk alleles of CD2AP, SPON1 and LOC39095 SNPs that were associated with differences in the respective patterns of brain atrophy, especially in the precuneus. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The aggregation and deposition of amyloid-β (Aβ) peptides into plaques is an early event in Alzheimer's disease (AD), which is followed by different aspects of neurodegeneration that can be measured in the cerebrospinal fluid (CSF) or plasma using neurofilament light (NFL), neurogranin (Ng), total Tau (T-Tau), and phosphorylated tau (P-Tau) levels. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Forecasted outcomes are compared with outcomes observed on candidate drugs, thus replacing a concomitant placebo group. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
However, a more recent work, derived in part from functional neuroimaging studies, has suggested that other brain structures make up a large-scale network that appears to support successful encoding and retrieval of episodic memories. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
What can be expected in normal aging, and where does normal aging stop and pathological neurodegeneration begin? 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The early identification of brain anatomy deviating from the normal pattern of growth and atrophy, such as in Alzheimer's disease (AD), has the potential to improve clinical outcomes through early intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many machine learning and pattern classification methods have been applied to the diagnosis of Alzheimer's disease (AD) and its prodromal stage, i.e., mild cognitive impairment (MCI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is a transitional stage between age-related cognitive decline and Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 33,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 33,380 records, built mostly from automated pulls of Europe PMC (67.7% of the library) and OpenAlex (15.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,047 records (3.1% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated